Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation-Reference-Cited by-同舟云学术

Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation

Published:2019-07-10 Issue:11 Volume:49 Page:1357-1361
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Sasaki Yoichi¹,Sakamori Ryotaro¹^ORCID,Yamada Ryoko¹,Shigekawa Minoru¹,Tahata Yuki¹,Makino Yuki¹,Nakabori Tasuku¹,Kodama Takahiro¹,Hikita Hayato¹^ORCID,Tatsumi Tomohide¹,Takehara Tetsuo¹^ORCID

Affiliation:

1. Department of Gastroenterology and HepatologyOsaka University Graduate School of Medicine Suita Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13379

Reference23 articles.

1. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

2. Novel approaches for molecular targeted therapy against hepatocellular carcinoma

3. Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion

4. Vitamin K and biosynthesis of protein and prothrombin;Hill RB;J Biol Chem,1968

5. Vitamin K‐Dependent Carboxylation

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of a Prethrombotic State in Patients with Hepatocellular Carcinoma, Using a Clot Waveform Analysis;Clinical and Applied Thrombosis/Hemostasis;2024-01

2. Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS/MS;Thoracic Cancer;2023-09-28

3. Anlotinib and fruquintinib co-administrated with warfarin increases the risk of bleeding: Studied from pharmacokinetic and pharmacodynamic perspectives;European Journal of Pharmaceutical Sciences;2023-09

4. Lenvatinib/warfarin interaction;Reactions Weekly;2020-01

5. Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9 * 1/*3 and VKORC1 ‐1639G/A genotype;Journal of Clinical Pharmacy and Therapeutics;2019-08-30